The information in this section is intended for visitors outside the United States.
Gilead Announces U.S. FDA Priority Review Designation for Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for Treatment of HIV
U.S. FDA Approves Expanded Labeling for Epclusa® (Sofosbuvir/Velpatasvir) for the Treatment of Chronic Hepatitis C in Patients Co-Infected with HIV
European Commission Grants Marketing Authorization for Gilead’s Vosevi® (Sofosbuvir/Velpatasvir/Voxilaprevir) for the Treatment of All Genotypes of Chronic Hepatitis C
Gilead Sciences Announces Third Quarter 2017 Dividend
Gilead Sciences Announces Second Quarter 2017 Financial Results
Gilead Announces Phase 3 Results for Investigational Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for Treatment of HIV
U.S. Food and Drug Administration Approves Gilead’s Vosevi™ (Sofosbuvir/Velpatasvir/Voxilaprevir) for Re-Treatment of Adults with Chronic Hepatitis C Virus
European Medicines Agency Validates Gilead’s Marketing Application for Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for Treatment of HIV
Gilead Sciences to Release Second Quarter 2017 Financial Results on Wednesday, July 26, 2017
European CHMP Adopts Positive Opinion for Gilead’s Vosevi® (Sofosbuvir/Velpatasvir/Voxilaprevir) for the Treatment of All Chronic Hepatitis C Genotypes
Gilead Submits New Drug Application to U.S. Food and Drug Administration for Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for HIV Treatment
Gilead Sciences to Present at the Goldman Sachs 38th Annual Global Healthcare Conference on Thursday, June 15
Gilead Sciences to Present at the 37th Annual William Blair Growth Stock Conference on Tuesday, June 13
Gilead’s Investigational Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for the Treatment of HIV-1 Meets Primary Endpoint in Four Phase 3 Studies
Gilead Sciences to Present at the Bank of America Merrill Lynch Healthcare Conference on Thursday, May 18
Gilead Sciences Announces Second Quarter 2017 Dividend
Gilead Sciences Announces First Quarter 2017 Financial Results
Gilead Announces Scientific Presentations Demonstrating Efficacy of Harvoni® (Ledipasvir/Sofosbuvir) in Special Patient Populations With HCV Infection
Gilead Presents Proof-of-Concept Data for GS-0976 in Nonalcoholic Steatohepatitis (NASH) at The International Liver Congress™ 2017
Gilead Presents Data at the International Liver Congress™ 2017 Supporting the Efficacy and Safety of Vemlidy in Patients with Chronic Hepatitis B After 96 Weeks, and Also After Switching From Viread
Gilead to Present Clinical and Preclinical Data on Nonalcoholic Steatohepatitis (NASH) at The International Liver Congress™ 2017
Gilead Sciences to Release First Quarter 2017 Financial Results on Tuesday, May 2, 2017
U.S. FDA Approves New Indications for Harvoni® and Sovaldi® in Pediatric Patients 12 Years and Older with Chronic Hepatitis C Infection
Gilead Sciences to Present at the Barclays Global Healthcare Conference on Tuesday, March 14
Gilead Announces 144-Week Data Evaluating Safety and Efficacy of Genvoya® for Treatment of HIV-1 in Treatment-Naïve Adults
Gilead Announces Findings from New Preclinical Study Evaluating Novel Class of HIV Capsid Inhibitors
Gilead Presents New Phase 2 Data on Bictegravir, an Investigational Integrase Strand Transfer Inhibitor for the Treatment of HIV
Gilead Sciences to Present at the RBC Capital Markets 2017 Global Healthcare Conference on Wednesday, February 22
Gilead Sciences Announces 10 Percent Increase in First Quarter 2017 Dividend
Gilead Sciences Announces Fourth Quarter and Full Year 2016 Financial Results
Gilead Sciences to Release Fourth Quarter and Full Year 2016 Financial Results on Tuesday, February 7, 2017
European Medicines Agency Validates Gilead’s Marketing Authorization Application for Investigational Chronic Hepatitis C Therapy Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX)
European Commission Grants Marketing Authorization for Gilead’s Vemlidy® (Tenofovir Alafenamide, TAF) for the Treatment of Chronic Hepatitis B Virus Infection
Gilead Awards More Than $22 Million in Grants to Support HIV Cure Research
Alessandro Riva, MD, to Join Gilead as Senior Vice President, Hematology and Oncology Therapeutic Area Head
2015 Annual Review